Natalizumab ELISA Assay Kit


The Natalizumab ELISA Assay Kit is intended as an analytical tool for quantitative determination of Natalizumab in serum, plasma and cell culture supernatant.

SKU: KBI1020 Categories: , , Tag:

Natalizumab ELISA Assay Kit

The Natalizumab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: 2.5 ng/mL
Standard Range: 2.5-160 ng/ml
Incubation Time: 2.5 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µL
Alternative Name: Tysabri

Assay Principle to Natalizumab ELISA

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Natalizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Natalizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Natalizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Natalizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Sample Preparation and Storage:
Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at – 20°C. For Cell Culture Supernatant – If necessary, centrifuge to remove debris prior to analysis. Samples can be stored at -20°C or -80⁰C. Avoid repeated freeze-thaw cycles.

Related Products to Natalizumab ELISA Assay Kit

Anti-Natalizumab (Tysabri) ELISA
Omalizumab (Xolair) ELISA Assay Kit
Tocilizumab (Actermra) ELISA Assay

Additional Information

Assay Background

Natalizumab (Tysabri®) is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin used in the treatment of multiple sclerosis and Crohn’s disease. Tysabri® and was previously named Antegren®. Natalizumab is administered by intravenous infusion every 28 days and reduces the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations